Zai Lab, argenx report 15.4-point ALKIVIA improvement
Share
Zai Lab (NASDAQ:ZLAB) and argenx (NASDAQ:ARGX) reported that VYVGART Hytrulo met the Phase 3 ALKIVIA primary endpoint with a 15.4-point TIS advantage over placebo at Week 52.
Zai Lab (NASDAQ:ZLAB) and argenx (NASDAQ:ARGX) reported that VYVGART Hytrulo met the Phase 3 ALKIVIA primary endpoint with a 15.4-point TIS advantage over placebo at Week 52.
Zai Lab (NASDAQ:ZLAB) announced that China’s National Medical Products Administration has approved its Biologics License Application for TIVDAK, an injectable therapeutic targeting adult patients with recurrent or metastatic cervical cancer.
Zai Lab (NASDAQ:ZLAB) has received European orphan drug designation for its antibody-drug conjugate targeting 375,000 annual lung cancer cases.
Zai Lab Limited (NASDAQ:ZLAB) received marketing authorization from China’s National Medical Products Administration (NMPA) for Cobenfy, a groundbreaking treatment for schizophrenia in adults.
